<DOC>
	<DOCNO>NCT01205724</DOCNO>
	<brief_summary>This trial conduct globally . The aim clinical trial investigate safety pharmacokinetics ( determination concentration administer medication blood time ) NNC 0129-0000-1003 previously treat subject severe haemophilia A .</brief_summary>
	<brief_title>Safety Pharmacokinetics NNC 0129-0000-1003 Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Haemophilia A Body Mass Index ( BMI ) 35 kg/m2 History minimum 150 exposure day ( EDs ) FVIII product ( prophylaxis/prevention/surgery/ondemand ) Any history FVIII inhibitor Surgery plan occur trial Platelet count le 50,000 platelets/microlitre ( assessed laboratory ) Congenital acquire coagulation disorder haemophilia A</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>